Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
5.54
-0.31 (-5.30%)
Feb 21, 2025, 4:00 PM EST - Market closed
Acrivon Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Acrivon Therapeutics stock have an average target of 22.4, with a low estimate of 16 and a high estimate of 30. The average target predicts an increase of 304.33% from the current stock price of 5.54.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 14, 2024.
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 31, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $28 → $27 | Buy | Maintains | $28 → $27 | +387.36% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +297.11% | Nov 14, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $17 | Buy | Reiterates | $17 | +206.86% | Sep 16, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Hold → Strong Buy Upgrades $16 | Hold → Strong Buy | Upgrades | $16 | +188.81% | Sep 16, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
350.43K
EPS This Year
-2.56
from -2.74
EPS Next Year
-2.85
from -2.56
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | 3.2M | 60.2M | |||
| Avg | n/a | 350,431 | 13.9M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | 17,091.7% | |||
| Avg | - | - | 3,858.0% | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.47 | -2.19 | -1.93 | |||
| Avg | -2.56 | -2.85 | -2.88 | |||
| Low | -3.02 | -3.87 | -3.33 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.